vTv Therapeutics Inc.
VTVT Healthcare Biotechnology
In the quarter to June 2026, revenue grew 409,222.2%, EPS fell 14.1% and free cash flow fell 124.6%, each against the same quarter a year earlier.
Follow VTVT
vTv Therapeutics Inc. (VTVT) EV/Sales
As of 16 October 2026, vTv Therapeutics Inc. (VTVT) trades at a EV/Sales of 6.5×. Over the past ten years it has ranged from −73.7× (March 2016) to 4,969× (December 2020); the current reading is higher than 25% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 42.8× | 93.58% |
| FY2022 | 22.1× | 76.20% |
| FY2021 | 12.6× | (3.23%) |
| FY2020 | 13.0× | (29.81%) |
| FY2019 | 18.5× | 510.61% |
| FY2018 | 3.0× | (98.58%) |
| FY2017 | 214× | 1,685.89% |
| FY2016 | 12.0× | — |
| FY2015 | −48.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 10.4× | (75.61%) |
| Dec 2024 | 42.8× | 141.71% |
| Mar 2024 | 17.7× | (19.91%) |
| Dec 2022 | 22.1× | 205.96% |
| 29 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LENZ LENZ Therapeutics, Inc. compare | −5.4× |
| SEER Seer, Inc. compare | −2.9× |
| TNXP Tonix Pharmaceuticals Holding Corp. compare | −2.3× |
| FHTX Foghorn Therapeutics Inc. compare | −0.5× |
| ENGN enGene Therapeutics Inc compare | n/m |
| CYTT Cyteir Therapeutics, Inc. compare | n/m |
| VTVT vTv Therapeutics Inc. | 6.5× |
| GNLX Genelux Corporation compare | 8.8× |
| INO Inovio Pharmaceuticals, Inc. compare | 157× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)